• NanoViricides posted a net loss of $1.99 million, or $0.09 per share, for the quarter ended March 31, 2026, narrowing from a net loss of $2.22 million, or $0.14 per share, a year earlier.
• Research and development expense in the quarter edged up to $1.29 million from $1.28 million, while general and administrative expense dropped to $744,276 from $966,905.
• Cash and cash equivalents rose to $3.21 million at March 31, 2026 from $1.56 million at June 30, 2025; stockholders’ equity was $9.15 million.
• Orphan Drug Designation for NV-387 as a measles treatment was granted by FDA on April 27, 2026, with decisions pending on orphan applications for mpox and smallpox; a Rare Pediatric Disease Drug designation application for measles was filed in March 2026.
• Focus remained on starting a Phase II NV-387 mpox trial in Democratic Republic of Congo, with site preparation and final documentation underway, while also advancing plans for Phase II studies in viral acute respiratory infections in India and pediatric RSV regulatory work in the US.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-061499), on May 15, 2026, and is solely responsible for the information contained therein.